Multicenter, Double Blind, Randomized, Placebo Controlled Study of Testogel (Testosterone 50–100mg) to Evaluate Its Efficacy and Safety in Men Presenting With Typical Symptoms of Partial Androgen Deficiency of Aging Males (PADAM) Over a Period of 6 Months With 12 Months Open Label Follow-up.

Trial Profile

Multicenter, Double Blind, Randomized, Placebo Controlled Study of Testogel (Testosterone 50–100mg) to Evaluate Its Efficacy and Safety in Men Presenting With Typical Symptoms of Partial Androgen Deficiency of Aging Males (PADAM) Over a Period of 6 Months With 12 Months Open Label Follow-up.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jul 2009 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
    • 07 Oct 2008 Actual number of patients (363) and trial identifier (91297) added as reported by CT.gov
    • 07 Oct 2008 Actual end date (Oct 2007) added as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top